peptide yy and obesity Attenuated peptide YY release in obese subjects is associated with reduced satiety - Peptide yyreceptor Peptide YY Peptide YY and Obesity: Unraveling the Gut Hormone's Role in Weight Regulation

Peptide YYfoods The intricate relationship between peptide YY (PYY) and obesity is an area of intense scientific interest, with emerging evidence highlighting its potential as both a contributing factor to weight gain and a promising therapeutic target. This gut hormone, released primarily from the intestines in response to fat and carbohydrate intake, plays a crucial role in appetite regulation and satiety.The role of peptide YY in integrative gut physiology and... Understanding the nuances of peptide YY's function is key to developing effective strategies for managing obesityThe Association of Serum Total Peptide YY (PYY) with Obesity ....

Peptide YY is a peptide hormone that is secreted by endocrine cells in the gastrointestinal tract, particularly in the ileum and colon. Its release is triggered by the presence of nutrients, such as fats and carbohydrates, in the small intestine. Once released into the bloodstream, PYY travels to the brain and acts on specific receptors, primarily the Y2 receptor pathways, to signal satiety and reduce food intake. This mechanism is vital for preventing overeating and maintaining energy balance.

However, research indicates that in individuals with obesity, the normal functioning of peptide YY may be disrupted.Peptide YY and Glucagon-like Peptide-1 Secretion in Obesity. @article ...Attenuated peptide YY release in obese subjects is associated with reduced satiety. Several studies suggest that low circulating PYY concentrations can predispose individuals to the development and maintenance of obesity.Inhibition of Food Intake in Obese Subjects by Peptide YY3 ... For instance, a study by Karra et al. (2008) indicated that low circulating PYY levels are associated with a higher predisposition to obesity. Similarly, Wilbrink et al. (2024) hypothesized that obesity is linked to attenuated systemic and tissue concentrations of gut peptides like PYY and GLP-1.作者：A De Silva·2012·被引用次数：467—This review article provides an overview of the central control of food intake and the role ofPYYand GLP-1 in appetite control. This means that individuals struggling with their weight may not experience the same level of satiety signals from PYY, potentially leading to increased calorie consumption作者：RL Batterham·2003·被引用次数：2178—These findings suggest thatPYY may be a useful treatment for obesity. PYY acts on the same hypothalamic neural circuits as leptin to regulate food intake..

Further evidence supporting the link between low peptide YY levels and obesity comes from studies observing obese persons who have been found to have lower baseline PYY levels than lean individuals.2025年9月12日—Adding PYY1875 to semaglutide offered only modestweight lossinobesitytrials, with GI side effects limiting tolerability. Despite this, they appear sensitive to the anorectic effects of exogenously administered PYY (Pfluger et al., 2007; Cahill et al., 2014). This suggests that while their natural PYY production or signaling might be compromised, their bodies can still respond to external PYY to promote feelings of fullness and reduce appetite.

The therapeutic potential of peptide YY in combating obesity is a significant area of research. Studies have explored the use of PYY as a treatment for obesity, with promising results2019年6月8日—Combined GLP-1, Oxyntomodulin, and Peptide YY improves body weight and glycemia in obesityand prediabetes/type 2 diabetes: a randomized, single-blinded, .... For example, Batterham et alPeptide YY in Type 2 Diabetes: A Complementary Gut .... (2003) found that PYY may be a useful treatment for obesity, acting on the same hypothalamic neural circuits as leptin to regulate food intake. More recent research has focused on peptide YY analogues, which are modified versions of the hormone designed for enhanced stability and efficacy.作者：J Wilbrink·2024·被引用次数：2—We hypothesize thatobesityis associated with attenuated systemic and tissue concentrations of the gutpeptides PYYand GLP-1. Tan et alLong-acting PYY 3 −36 analogue with semaglutide for .... (2021) noted that gut hormones like peptide YY (PYY) have emerged as candidate therapies for obesity by activating natural satiety pathways and reducing food intake.

Combinatorial therapies involving peptide YY and other gut hormones are also showing significant promise. A pilot study by Oertel et al.作者：J Wilbrink·2024·被引用次数：2—We hypothesize thatobesityis associated with attenuated systemic and tissue concentrations of the gutpeptides PYYand GLP-1. (2024) demonstrated that a combined treatment with a non-selective PYY analog and semaglutide led to greater body weight loss compared to semaglutide alone. Another study by Wulff et al.作者：J Wilbrink·2024·被引用次数：2—Objective: The regulation of food intake is disturbed inobesity, possibly resulting from alterations in gutpeptidesecretion. (2025) indicated that combined GLP-1, oxyntomodulin, and Peptide YY improves body weight and glycemia in obesity and prediabetes/type 2 diabetes. These findings suggest that synergistic effects between different gut hormones can lead to enhanced weight loss outcomes.

The role of peptide YY in appetite regulation extends beyond just reducing food intake. It can also influence energy expenditure and metabolism. For instance, increased PYY levels, such as those observed after aerobic exercise, have been shown to reduce subsequent energy intake in both lean and obese individuals (Cooper et al.2012年9月6日—Obese persons have been found to have lower baseline PYY levelsthan lean persons but are sensitive to the anorectic effects of exogenously ..., 2014). This highlights the multifaceted impact of PYY on energy balance.

While the potential of peptide YY in treating obesity is substantial, challenges remainAdding PYY1875 to Semaglutide Yields Limited Weight .... Some studies have indicated that while PYY3-36 levels are often reduced in individuals with obesity, they typically return to normal levels in certain contexts (Chichura et al., 2023). Furthermore, the development of long-acting PYY analogs is an ongoing area of research.Weight loss during oligofructose supplementation is ... Wulff et al. (2025) noted that adding PYY1875 to semaglutide offered only modest weight loss in obesity trials, with gastrointestinal side effects limiting tolerability. This underscores the need for further optimization of PYY-based therapies to maximize efficacy and minimize adverse effects.

It is also important to note that while PYY is a potent appetite suppressant, it does not directly induce insulin release like GLP-1. However, it confers metabolic advantages by suppressing appetite through Y2 receptor pathways (Nguyen et alPeptide YY and Glucagon-like Peptide-1 Secretion in Obesity., 2025). This distinction is crucial when considering combination therapies for metabolic disorders like obesity and type 2 diabetes.

In conclusion, peptide YY is a critical gut hormone involved in regulating appetite and satietyWeight loss during oligofructose supplementation is .... Evidence strongly suggests that alterations in PYY levels and signaling contribute to the pathophysiology of obesity. Research into PYY as a therapeutic agent, including the development of novel analogs and combination therapies with other gut hormones like GLP-1, holds significant promise for addressing this global health challenge. Continued investigation into the complex interplay between peptide YY and obesity will undoubtedly pave the way for more effective weight-loss strategies and improved metabolic health.Peptide YY in Type 2 Diabetes: A Complementary Gut ...